• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xeris Pharmaceuticals Inc (NQ: XERS )

    2.250 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.250
    Bid (Size) 2.240 (5)
    Ask (Size) 2.260 (1)
    Prev. Close 2.250
    Today's Range 2.250 - 2.250
    52wk Range 1.460 - 3.260
    Shares Outstanding 66,497,370
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -0.66%
    -0.66%
    1 Month
    -0.22%
    -0.22%
    3 Month
    +5.14%
    +5.14%
    6 Month
    -0.66%
    -0.66%
    1 Year
    -11.76%
    -11.76%

    More News

    Read More
    Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
    Via ACCESSWIRE
    Earnings Outlook For Xeris Biopharma Holdings
    Via Benzinga
    Xeris to Participate in the Jefferies Global Healthcare Conference
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Why Are Xeris Biopharma Shares Moving Monday?
    Via Benzinga
    Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Earnings Scheduled For March 6, 2024
    Via Benzinga
    Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
    Via InvestorPlace
    Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
    Via InvestorPlace
    Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.